Shionogi has been granted a patent for a solid dosage form containing a specific compound, stabilizer, sugar alcohol/sugar, water-soluble polymer, and inorganic substance. The form exhibits good stability, suspensibility in water, and fluidity. GlobalData’s report on Shionogi gives a 360-degree view of the company including its patenting strategy. Buy the report here.

Smarter leaders trust GlobalData


Data Insights Shionogi & Co Ltd - Company Profile

Buy the Report

Data Insights

The gold standard of business intelligence.

Find out more

According to GlobalData’s company profile on Shionogi, Cancer treatment biomarkers was a key innovation area identified from patents. Shionogi's grant share as of February 2024 was 58%. Grant share is based on the ratio of number of grants to total number of patents.

Solid dosage form with good stability, suspensibility, and fluidity

Source: United States Patent and Trademark Office (USPTO). Credit: Shionogi & Co Ltd

A recently granted patent (Publication Number: US11925648B2) discloses a solid dosage form containing a compound represented by formula (I). The dosage form may include alkali metal chloride, specifically sodium chloride or potassium chloride, along with sugar alcohols, sugars, or a combination of both such as isomalt, maltitol, mannitol, and others. Additionally, the solid dosage form may contain a water-soluble polymer, particularly cellulose-based polymers like hypromellose, and may also include substances like hydrated silicon dioxide, light anhydrous silicic acid, and talc.

Furthermore, the patent describes variations in the composition of the solid dosage form, ranging from the amount of the compound represented by formula (I) to the inclusion of flavoring agents, lubricants, suspending agents, fluidizing agents, and binders. The dosage form may also contain specific combinations of ingredients like talc as a lubricant, hypromellose as a suspending agent, and polyvinyl pyrrolidone as a binder. The dosage form can range from 1 mg to 80 mg of the compound represented by formula (I) and may include mannitol and maltitol in certain formulations. Overall, the patent provides detailed specifications for the composition and preparation of the solid dosage form, offering a comprehensive guide for manufacturing a pharmaceutical product with specific ingredients and proportions.

To know more about GlobalData’s detailed insights on Shionogi, buy the report here.

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies